Use and effectiveness of dapagliflozin in routine clinical practice. An Italian multicenter retrospective study

Andrea Giaccari, Gian Paolo Fadini, Giancarlo Zatti, Ileana Baldi, Daniele Bottigliengo, Agostino Consoli, Giorgio Sesti, Angelo Avogaro

Risultato della ricerca: Contributo in rivistaArticolo in rivista

20 Citazioni (Scopus)

Abstract

In randomized controlled trials (RCTs), SGLT-2 inhibitors (SGLT2i) showed glycaemic and extra-glycaemic benefits. The DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes) was a multicenter retrospective study designed to evaluate baseline characteristics of patients receiving dapagliflozin versus selected comparators (DPP-4 inhibitors, gliclazide, or GLP-1 receptor agonists), and drug effectiveness in routine clinical practice. From a population of 281,217 patients, the analysis included 17,285 initiating dapagliflozin or comparator glucose lowering medications (GLM), 6751 of whom had a follow-up examination. At baseline, patients starting dapagliflozin were younger, had a longer disease duration, higher HbA1c, and a more complex history of previous GLM use, but the clinical profile of patients receiving dapagliflozin was changing during the study period. Dapagliflozin reduced HbA1c by 0.7%, body weight by 2.7 kg, and systolic blood pressure by 3.0 mm Hg. Effects of comparator GLM were also within the expected range based on RCTs. This real-world study demonstrates an initial channelling of dapagliflozin to difficult-to-treat patients. Nonetheless, dapagliflozin provided significant benefits on glucose control, body weight, and blood pressure that were in line with findings from RCTs.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaDiabetes, Obesity and Metabolism
DOI
Stato di pubblicazionePubblicato - 2018

Keywords

  • 3003
  • Antidiabetic drugs
  • Drug Discovery3003 Pharmaceutical Science
  • Glycemic control
  • Glycosylated hemoglobin
  • Pharmacology
  • Precision medicine
  • Sodium-glucose cotransporter 2 inhibitors
  • Type 1 diabetes mellitus
  • Type 2 diabetes mel­litus
  • Weight reduction

Fingerprint Entra nei temi di ricerca di 'Use and effectiveness of dapagliflozin in routine clinical practice. An Italian multicenter retrospective study'. Insieme formano una fingerprint unica.

Cita questo